Hemogenyx Pharmaceuticals PLC Stock: price and insider trades · United Kingdom
No insider purchase over the last 90 days. The latest, by Andrew Wright, was filed 30 May 2022.
Hemogenyx Pharmaceuticals PLC: what insiders have been doing
Hemogenyx Pharmaceuticals PLC is a listed company based in London, United Kingdom. Its directors and officers file their transactions with RNS (LSE). Hemogenyx Pharmaceuticals PLC has had no insider filing for more than a year; the last one goes back to 30 May 2022.
Since 2017, the database holds 12 purchases and no sales by insiders of the company.
Source: insider filings from RNS (LSE). Past trades are no guide to future returns.
Key facts
Headquarters: London, United Kingdom
Source: Wikidata (CC0).
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 1,284,889 shares@ £0.014425.2% of flowLondon Stock Exchange XLONISIN GB00BYX3WZ24FCA-NSM:4386968Canonical exit: 25 Aug 2022 (T+90)
- 1,088,120 shares@ £0.018326.8% of flowLondon Stock Exchange XLONISIN GB00BYX3WZ24FCA-NSM:3978911Canonical exit: 16 Aug 2021 (T+90)
- 94,882 shares@ £0.06037.7% of flowLondon Stock Exchange XLONISIN GB00BYX3WZ24FCA-NSM:3903927Canonical exit: 6 Jun 2021 (T+90)
- 90,554 shares@ £0.0568100.0% of flowLondon Stock Exchange XLONISIN GB00BYX3WZ24FCA-NSM:3641510-0Canonical exit: 27 Sept 2020 (T+90)
- 344,150 shares@ £0.0578100.0% of flowLondon Stock Exchange XLONISIN GB00BYX3WZ24FCA-NSM:3641510-1Canonical exit: 27 Sept 2020 (T+90)
- 257,069 shares@ £0.019451.2% of flowLondon Stock Exchange XLONISIN GB00BYX3WZ24FCA-NSM:LSE20200131070005_14405233_20200331164953410_30379Canonical exit: 29 Apr 2020 (T+90)
- 840,336 shares@ £0.023866.8% of flowLondon Stock Exchange XLONISIN GB00BYX3WZ24FCA-NSM:LSE20190501070014_14058463_20200326185143262_29646Canonical exit: 29 Jul 2019 (T+90)
- 18,002,568 shares@ £0.0004100.0% of flowOutside of a trading venueFCA-NSM:LSE20180411171543_13601100_20200330111354151_16832
- 200,000 shares@ £0.02126.0% of flowLondon Stock ExchangeISIN GB00BYX3WZ24FCA-NSM:LSE20180212070005_13528927_20200330111413354_17975Canonical exit: 10 May 2018 (T+90)
- 26,800 shares@ £0.0237100.0% of flowLondon Stock ExchangeISIN GB00BYX3WZ24FCA-NSM:LSE20180207070003_13524031_20200330111413568_22247Canonical exit: 6 May 2018 (T+90)
- 400,000 shares@ £0.029672.1% of flowLondon Stock ExchangeISIN GB00BYX3WZ24FCA-NSM:LSE20171011070004_13392501_20200330131537664_7159Canonical exit: 4 Jan 2018 (T+90)
- 10,000 shares@ £0.0311.9% of flowLondon Stock ExchangeISIN GB00BYX3WZ24FCA-NSM:LSE20171010070004_13391128_20200330131537618_6138-0Canonical exit: 4 Jan 2018 (T+90)
- 155,000 shares@ £0.0314100.0% of flowLondon Stock ExchangeISIN GB00BYX3WZ24FCA-NSM:LSE20171010070004_13391128_20200330131537618_6138-1Canonical exit: 4 Jan 2018 (T+90)
13 of 13 declarations
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals PLC is a biopharmaceutical company focused on developing innovative treatments for blood diseases. It is listed on the London Stock Exchange (XLON).
